Skip to main content
    C

    cbdMD Inc (YCBD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • AMEX

    $0.36
    -0.02 (-4.28%)

    Market Cap: $5.02M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    cbdMD Inc (YCBD) Earnings: Report Dates and Results

    Updated Aug 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    cbdMD (YCBD) is expected to report earnings on Dec 18, 2026. In the quarter ended Jun 30, 2026, cbdMD reported EPS of -$0.11, below the -$0.03 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    32%(9/28)
    Avg Surprise
    -105.72%

    Upcoming Estimates

    Reports Dec 18, 2026 (est.)Period ending Sep 30, 2026
    EPS Consensus-$0.09
    Range-$0.09 - -$0.09
    3 analysts
    Revenue Consensus
    $5.83M
    Range$5.60M - $6.00M
    3 analysts
    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.06
    Range-$0.06 - -$0.06
    1 analysts
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago-$0.10+40.0%
    Current-$0.06
    Revenue Consensus
    $6.30M
    Range$6.30M - $6.30M
    1 analysts

    Next Report

    YCBD has an expected report date of Dec 18, 2026.

    YCBD Earnings Call

    The latest YCBD earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 28 quarters below that had an estimate, YCBD beat 9 and missed 19. Revenue for the quarter ended Jun 30, 2026 was $5.55M, up 20.4% from $4.61M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.11-$0.03-$0.03 - -$0.03-266.67%MissN/A11 up, 0 downAug 13, 2026$5.55M
    Mar 31, 2026-$0.08-$0.05-$0.05 - -$0.05-60.00%MissN/A11 up, 0 downMay 14, 2026$5.64M
    Dec 31, 2025-$0.04-$0.06N/A+33.33%BeatN/A10 up, 0 downFeb 17, 2026$5.02M
    Sep 30, 2025-$0.08-$0.07-$0.07 - -$0.07-14.29%MissN/A11 up, 0 downDec 19, 2025$4.72M
    Jun 30, 2025-$0.21-$0.16N/A-31.25%MissN/AN/A0 up, 0 downAug 14, 2025$4.61M
    Mar 31, 2025-$1.90-$1.60N/A-18.75%MissN/AN/A0 up, 0 downMay 15, 2025$4.75M
    Dec 31, 2024-$1.76-$2.96N/A+40.54%BeatN/AN/A0 up, 0 downFeb 13, 2025$5.11M
    Sep 30, 2024-$0.29-$0.45N/A+34.82%BeatN/AN/A0 up, 0 downDec 27, 2024$4.56M
    Jun 30, 2024-$1.20-$4.96-$4.96 - -$4.96+75.81%BeatN/A10 up, 0 downAug 14, 2024$5.17M
    Mar 31, 2024-$10.80-$6.00-$6.00 - -$6.00-80.00%MissN/A10 up, 0 downMay 15, 2024$4.38M
    Dec 31, 2023-$5.21-$5.92-$5.92 - -$5.92+11.99%BeatN/A10 up, 0 downJan 29, 2024$5.38M
    Sep 30, 2023-$1.21-$0.76N/A-59.21%MissN/AN/A0 up, 0 downDec 22, 2023$5.71M
    Jun 30, 2023-$9.28-$28.80N/A+67.78%BeatN/AN/A0 up, 0 downAug 10, 2023$6.12M
    Mar 31, 2023-$0.03-$0.04N/A+25.00%BeatN/AN/A0 up, 0 downMay 15, 2023$6.24M
    Dec 31, 2022-$28.80-$126.00N/A+77.14%BeatN/AN/A0 up, 0 downFeb 13, 2023$6.09M
    Sep 30, 2022-$0.26-$0.03N/A-759.00%MissN/AN/A0 up, 0 downDec 15, 2022$7.86M
    Jun 30, 2022-$198.00-$18.00N/A-1000.00%MissN/AN/A0 up, 0 downAug 11, 2022$8.59M
    Mar 31, 2022-$36.00-$14.40N/A-150.00%MissN/AN/A0 up, 0 downMay 13, 2022$9.63M
    Dec 31, 2021-$126.00-$14.40N/A-775.00%MissN/A10 up, 0 downFeb 10, 2022$9.32M
    Sep 30, 2021-$0.07-$0.04-$0.07 - -$0.02-75.00%MissN/A20 up, 0 downDec 17, 2021$9.79M
    Jun 30, 2021-$42.12-$21.60-$21.62 - -$7.21-95.00%MissN/A2N/AAug 12, 2021$10.56M
    Mar 31, 2021-$28.30-$14.40-$14.41 - -$7.21-96.53%MissN/A2N/AMay 12, 2021$11.80M
    Dec 31, 2020-$10.62-$3.60-$7.21 - -$3.60-195.00%MissN/A2N/AFeb 9, 2021$12.33M
    Sep 30, 2020-$0.14-$0.01-$0.01 - -$0.01N/AN/A-117.7%1N/ADec 22, 2020$11.70M
    Jun 30, 2020-$10.04-$9.00-$18.02 - -$7.21-11.56%MissN/A2N/AAug 12, 2020$10.64M
    Mar 31, 2020-$55.87-$25.20-$46.85 - -$14.41-121.71%MissN/A3N/AMay 18, 2020$9.40M
    Dec 31, 2019-$51.05-$46.62-$68.47 - -$32.43-9.50%MissN/A3N/AFeb 13, 2020$10.15M
    Sep 30, 2019$0.79-$0.17-$0.18 - -$0.17+564.71%BeatN/A2N/ADec 18, 2019$9.54M
    Jun 30, 2019-$428.40-$36.00N/AN/AN/A-1428100.0%1N/AAug 14, 2019$8.01M
    Mar 31, 2019-$31.10-$18.00N/A-72.78%Miss-18394.1%1N/AMay 15, 2019$5.64M
    Dec 31, 2018-$0.06N/AN/AN/AN/AN/AN/AN/AFeb 14, 2019$465687
    Sep 30, 2018-$0.10N/AN/AN/AN/AN/AN/AN/ADec 12, 2018N/A
    Jun 30, 2018$0.03N/AN/AN/AN/AN/AN/AN/AAug 14, 2018$3.20M
    Mar 31, 2018$0.17N/AN/AN/AN/AN/AN/AN/AMay 15, 2018$3.08M
    Dec 31, 2017-$0.17N/AN/AN/AN/AN/AN/AN/AFeb 14, 2018$2.09M
    Sep 30, 2017-$0.03N/AN/AN/AN/AN/AN/AN/ADec 26, 2017N/A
    Mar 31, 2017-$0.13N/AN/AN/AN/AN/AN/AN/AMay 4, 2017$5.23M
    Last 37 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was -$0.23, after -$3.95 the year before. It was -$0.16 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026-$0.23N/A
    Sep 30, 2025-$3.95N/A
    Sep 30, 2024-$17.50N/A
    Sep 30, 2023-$39.32N/A
    Sep 30, 2022-$360.26N/A
    Sep 30, 2021-$81.11N/A
    Sep 30, 2020-$117.10N/A
    Sep 30, 2019-$458.77N/A
    Sep 30, 2018-$0.07N/A
    Sep 30, 2017-$0.16N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,200 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20264,1735
    2026Q1Mar 31, 20262,1524
    2025Q4Dec 31, 20253,7146
    2025Q2Jun 30, 20253,2635
    2025Q1Mar 31, 20252,9445
    2024Q3Sep 30, 20242,7325

    2026Q2 Earnings Call

    Opening remarks

    Bradley Whitford Chief Accounting Officer Thank you, Operator, and thank you all for joining cbdMD's March 31, 2026, Second Quarter of Fiscal 2026 Earnings Call and Update. On the call today, we also have Ronan Kennedy, our Chief Executive Officer and Chief Financial Officer. We'd like to remind everyone that various remarks about future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. cbdMD cautions that these forward-looking statements are subject to risks and uncertainties that may cause our actual results to differ materially from those indicated, including risks described in the company's annual report on Form 10-K for the second quarter ended March 31, 2026, and our other filings with the SEC, all of which can be reviewed on the company's website at www.cbdmd.com or on the SEC's website at www.sec.gov. Any forward-looking statements made on this conference call speak only as of today's date, Thursday, May 14, 2026, and cbdMD does not intend to update any of these forward-looking statements to reflect events or circumstances that would occur after today's date, except as may be required by federal securities laws. With that, I'd like to turn the call over to Ronan.

    Ronan Kennedy CEO & CFO Good afternoon, everyone, and thank you for joining us. The second quarter of fiscal 2026 was another step forward for cbdMD and one of the most active quarters we've had in years, both operationally and across the regulatory landscape we operate in. Let me start with the headline. We delivered another consecutive quarter of sequential revenue growth, with net sales of $5.6 million. That's up 19% year-over-year and 12% sequentially from the first quarter of 2026. Importantly, that growth was not solely driven by our acquisition of Bluebird Botanicals. Excluding Bluebird, our core business grew approximately $0.5 million versus the prior year and approximately $300,000 sequentially. And even excluding Bluebird, our core revenue this quarter was the highest quarterly revenue we've generated since our first fiscal quarter in 2024, the December 2023 quarter. That continued core growth quarter after quarter is the most important indicator that the reset work we've done over the past several years is showing through in results. From a channel perspective, direct-to-consumer remained our largest channel at approximately 67% of revenue, with wholesale growing to 33% of revenue. Wholesale was up 65% year-over-year reflecting continued execution in our core cbdMD brand and ongoing progress with our Oasis TSC beverage brand. In mid-January, we closed our acquisition of the assets of Bluebird Botanicals, a respected and long-standing CBD brand.

    Frequently Asked Questions About YCBD

    When is cbdMD's next earnings date?

    cbdMD's next earnings report is expected for Dec 18, 2026.

    Did YCBD beat earnings estimates last quarter?

    No. cbdMD reported EPS of -$0.11 for the quarter ended Jun 30, 2026, below the -$0.03 estimate by 266.67%.

    What EPS do analysts expect from YCBD next quarter?

    The consensus EPS estimate for cbdMD for the quarter ended Sep 30, 2026 is -$0.09 from 3 analysts, with estimates from -$0.09 to -$0.09.

    How often does YCBD beat earnings estimates?

    cbdMD beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -35.28%.